Genmab A/S (GMAB) News Today $19.32 +0.03 (+0.13%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Genmab stock falls amid AbbVie lawsuitMarch 24 at 9:23 AM | investing.comMadison Investment Advisors LLC Takes Position in Genmab A/S (NASDAQ:GMAB)Madison Investment Advisors LLC purchased a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 46,904 shares of the company's stock, valued at apprMarch 23 at 3:36 AM | marketbeat.comSignaturefd LLC Increases Position in Genmab A/S (NASDAQ:GMAB)Signaturefd LLC increased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 163.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,790 shares of the company's stock after acquiring an additional 12,890 shares during the period. SigMarch 22 at 4:26 AM | marketbeat.comGenmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.March 21, 2025 | globenewswire.comWhat is William Blair's Estimate for Genmab A/S Q1 Earnings?Genmab A/S (NASDAQ:GMAB - Free Report) - Investment analysts at William Blair issued their Q1 2026 earnings estimates for Genmab A/S in a report issued on Tuesday, March 18th. William Blair analyst M. Phipps expects that the company will post earnings of $0.37 per share for the quarter. William BMarch 20, 2025 | marketbeat.comGenmab A/S: Investigational Rinatabart Sesutecan (Rina-S) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian CancerMarch 19, 2025 | finanznachrichten.deGenmab A/S (GMAB): A Bull Case TheoryMarch 19, 2025 | msn.comGenmab A/S (NASDAQ:GMAB) Short Interest UpdateGenmab A/S (NASDAQ:GMAB - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 2,310,000 shares, an increase of 40.0% from the February 13th total of 1,650,000 shares. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is presently 1.7 days. Currently, 0.4% of the company's shares are short sold.March 17, 2025 | marketbeat.comInvestigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian CancerMarch 17, 2025 | businesswire.comPNC Financial Services Group Inc. Sells 18,776 Shares of Genmab A/S (NASDAQ:GMAB)PNC Financial Services Group Inc. cut its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 20.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,502 shares of the company's stock after selling 18,776 sharMarch 16, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Up - Still a Buy?Genmab A/S (NASDAQ:GMAB) Shares Gap Up - Here's What HappenedMarch 15, 2025 | marketbeat.comAtria Investments Inc Has $612,000 Holdings in Genmab A/S (NASDAQ:GMAB)Atria Investments Inc cut its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 39.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,301 shares of the company's stock after selling 19,174 sharesMarch 15, 2025 | marketbeat.comGenmab: GEN3014's Demise And Implications For The HexaBody PlatformMarch 14, 2025 | seekingalpha.comGenmab A/S announces board constitution and equity grantsMarch 14, 2025 | uk.investing.comWilliam Blair Forecasts Genmab A/S FY2029 EarningsGenmab A/S (NASDAQ:GMAB - Free Report) - Research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for Genmab A/S in a research report issued on Monday, March 10th. William Blair analyst M. Phipps anticipates that the company will earn $4.38 per share for the year.March 14, 2025 | marketbeat.comFY2028 EPS Estimates for Genmab A/S Lifted by William BlairGenmab A/S (NASDAQ:GMAB - Free Report) - Equities researchers at William Blair boosted their FY2028 EPS estimates for shares of Genmab A/S in a note issued to investors on Monday, March 10th. William Blair analyst M. Phipps now expects that the company will post earnings of $4.06 per share for thMarch 13, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Sold by Assetmark Inc.Assetmark Inc. decreased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 78.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,109 shares of the company's stock after selling 64,520 shares during the period. AsMarch 13, 2025 | marketbeat.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsMarch 12, 2025 | globenewswire.comConstitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in GenmabMarch 12, 2025 | globenewswire.comTruist Financial Cuts Genmab A/S (NASDAQ:GMAB) Price Target to $45.00Truist Financial decreased their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday.March 12, 2025 | marketbeat.comWilliam Blair Upgrades Genmab A (GMAB)March 12, 2025 | msn.comGenmab A/S (NASDAQ:GMAB) Shares Gap Down - Should You Sell?Genmab A/S (NASDAQ:GMAB) Shares Gap Down - What's Next?March 12, 2025 | marketbeat.comPassing of Genmab A/S' Annual General MeetingMarch 12, 2025 | globenewswire.comWilliam Blair Upgrades Genmab A/S (NASDAQ:GMAB) to OutperformWilliam Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday.March 12, 2025 | marketbeat.comGenmab Shares Fall After J&J Drops Blood-Cancer Treatment OptionMarch 12, 2025 | marketwatch.comGenmab A/S (NASDAQ:GMAB) Sees Unusually-High Trading Volume - Time to Buy?Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase - What's Next?March 11, 2025 | marketbeat.comGenmab says J&J not exercising option on HexaBody-CD38March 11, 2025 | finance.yahoo.comGenmab price target lowered to $45 from $50 at TruistMarch 11, 2025 | markets.businessinsider.comGenmab sinks as J&J opts not to develop Darzalex successor; stock upgradedMarch 11, 2025 | finance.yahoo.comGenmab upgraded to Outperform from Market Perform at William BlairMarch 10, 2025 | markets.businessinsider.comPositive Report for Genmab (GMAB) from William BlairMarch 10, 2025 | markets.businessinsider.comGenmab Stops Blood Cancer Treatment Development After J&J Won't License ItMarch 10, 2025 | marketwatch.comGenmab falls 7% to $22.44 after J&J declines option on HexaBody-CD38March 10, 2025 | markets.businessinsider.comJ&J will not exercise worldwide license option for HexaBody-CD38, says GenmabMarch 10, 2025 | msn.comGenmab stock tumbles after J&J opts out of licensing dealMarch 10, 2025 | investing.comGenmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38March 10, 2025 | businesswire.comGenmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38March 10, 2025 | globenewswire.com12,292 Shares in Genmab A/S (NASDAQ:GMAB) Purchased by Aigen Investment Management LPAigen Investment Management LP purchased a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 12,292 shares of the company's stock, valued at approximately $257,000. Other institMarch 10, 2025 | marketbeat.comMorgan Stanley Sticks to Their Hold Rating for Genmab (GMAB)March 6, 2025 | markets.businessinsider.comSanctuary Advisors LLC Sells 21,709 Shares of Genmab A/S (NASDAQ:GMAB)Sanctuary Advisors LLC cut its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 66.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,091 shares of the company's stock after selling 21,709 shares dMarch 6, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Genmab A/S (NASDAQ:GMAB - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twelve analysts that are currently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has giMarch 5, 2025 | marketbeat.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsMarch 4, 2025 | globenewswire.comTruist Financial Corp Sells 17,619 Shares of Genmab A/S (NASDAQ:GMAB)Truist Financial Corp reduced its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 39.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,557 shares of the company's stock after selling 17,619 shares during thMarch 3, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Sold by Oppenheimer Asset Management Inc.Oppenheimer Asset Management Inc. reduced its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 10.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 207,107 shares of the company's stock after seMarch 2, 2025 | marketbeat.com168,905 Shares in Genmab A/S (NASDAQ:GMAB) Bought by AIMZ Investment Advisors LLCAIMZ Investment Advisors LLC bought a new position in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 168,905 shares of the company's stock, valued at approximately $3,525,000. GMarch 1, 2025 | marketbeat.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsFebruary 28, 2025 | globenewswire.comGrant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in GenmabFebruary 28, 2025 | globenewswire.comY Intercept Hong Kong Ltd Buys 58,048 Shares of Genmab A/S (NASDAQ:GMAB)Y Intercept Hong Kong Ltd increased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 371.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,696 shares of the company's stock after purchasing an additFebruary 26, 2025 | marketbeat.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseFebruary 25, 2025 | globenewswire.comIs Genmab (GMAB) One of the Best Growth Stocks to Invest In According to Analysts?February 24, 2025 | msn.com Remove Ads Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address GMAB Media Mentions By Week GMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼0.790.63▲Average Medical News Sentiment GMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼105▲GMAB Articles Average Week Remove Ads Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenx News Today Beigene News Today BioNTech News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Intra-Cellular Therapies News Today Moderna News Today Dr. Reddy's Laboratories News Today Viatris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GMAB Stock Free GMAB Stock Alerts